Pointe Capital Management LLC Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

Pointe Capital Management LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 4.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,358 shares of the company’s stock after selling 65 shares during the quarter. Pointe Capital Management LLC’s holdings in Eli Lilly and Company were worth $792,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at about $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth about $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $40,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on LLY. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Truist Financial upped their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Trading Down 2.8 %

Shares of LLY traded down $20.94 during trading on Friday, reaching $734.97. 4,595,138 shares of the company traded hands, compared to its average volume of 2,629,045. The stock has a 50-day simple moving average of $761.06 and a 200-day simple moving average of $671.38. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The stock has a market cap of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the previous year, the company earned $1.62 earnings per share. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.